Clinical application of these findings is limited by the fact that we cannot selectively manipulate 53BP1 genetically, but pharmacologic manipulation of 53BP1 function, as seen in our data, could have implications on tumor sensitivity to radiation and PARPi. The gene discussed is TP53BP1; the disease is neoplasm.